http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lee Haeun,Lee Hanbi,Eum Sang Hun,Ko Eun Jeong,Min Ji-Won,Oh Eun-Jee,Yang Chul Woo,Chung Byung Ha 대한진단검사의학회 2023 Annals of Laboratory Medicine Vol.43 No.4
Background: The clinical significance of low-level donor-specific anti-HLA antibody (low-DSA) remains controversial. We investigated the impact of low-DSA on posttransplant clinical outcomes in kidney transplant (KT) recipients. Methods: We retrospectively reviewed 1,027 KT recipients, namely, 629 living donor KT (LDKT) recipients and 398 deceased donor KT (DDKT) recipients, in Seoul St. Mary’s Hospital (Seoul, Korea) between 2010 and 2018. Low-DSA was defined as a positive anti-HLA-DSA result in the Luminex single antigen assay (LABScreen single antigen HLA class I - combi and class II - group 1 kits; One Lambda, Canoga Park, CA, USA) but a negative result in a crossmatch test. We compared the incidence of biopsy-proven allograft rejection (BPAR), changes in allograft function, allograft survival, patient survival, and posttransplant infections between subgroups according to pretransplant low-DSA. Results: The incidence of overall BPAR and T cell-mediated rejection did not differ between the subgroups. However, antibody-mediated rejection (ABMR) developed more frequently in patients with low-DSA than in those without low-DSA in the total cohort and the LDKT and DDKT subgroups. In multivariate analysis, low-DSA was identified as a risk factor for ABMR development. Its impact was more pronounced in DDKT (odds ratio [OR]: 9.60, 95% confidence interval [CI]: 1.79–51.56) than in LDKT (OR: 3.76, 95% CI: 0.99–14.26) recipients. There were no significant differences in other outcomes according to pretransplant low-DSA. Conclusions: Pretransplant low-DSA has a significant impact on the development of ABMR, and more so in DDKT recipients than in LDKT recipients, but not on long-term outcomes.
A shape-code nanoplasmonic biosensor for multiplex detection of Alzheimer's disease biomarkers
Kim, Hanbi,Lee, Jong Uk,Song, Sojin,Kim, Soohyun,Sim, Sang Jun Elsevier 2018 Biosensors & bioelectronics Vol.101 No.-
<P><B>Abstract</B></P> <P>Alzheimer's disease (AD) is a neurodegenerative disease associated with the loss of nerve cells in the brain. The disease is affected by multifactorial pathways and leads to changes in related biomolecular levels as AD progresses. Therefore, AD should be diagnosed with combined detection of several lesions to improve accuracy. Amyloid beta 1–40, 1–42 and τ (tau) protein are milestones in AD pathology and can be used as main screening and diagnostic target markers. Here, we suggest a highly selective biosensor for detection of AD core biomarkers on one platform through distinct localized surface plasmon resonance (LSPR) depending on gold nanoparticles shapes, called a shape-code biosensor. This plasmonic sensor consists of only gold nanoparticles and antibody, but does not need additory methods for precise separation from multifarious samples and identification of markers. Under physiological condition, we determined a detection limit of 34.9fM for amyloid beta (Aβ) 1–40, 26fM for Aβ 1–42 and 23.6fM for τ protein corresponding to the ~ 1, ~ 2.23 and ~ 3.12nm of Rayleigh scattering peak shift on shape-code plasmon system for each biomarker in mimicked blood. This is the first highly sensitive shape-code biosensor to detect AD biomarkers which can be used to diagnose AD easily in the future.</P> <P><B>Highlights</B></P> <P> <UL> <LI> A shape-code biosensor is developed for multi-analysis of Alzheimer’s disease. </LI> <LI> Colorimetric characterization of shape-code AuNPs enables the multiplexed analysis. </LI> <LI> We detected femto molar range of hallmarks of Alzheimer’s disease in mimicked blood. </LI> <LI> This platform is diagnosable for diseases with great sensitive and multi-analysis. </LI> </UL> </P>
( Yohan Park ),( Hanbi Lee ),( Eun Jeong Ko ),( Sua Lee ),( Tae Hyun Ban ),( Ji-won Min ),( Hye-eun Yoon ),( Eun-jee Oh ),( Chul Woo Yang ),( Byung Ha Chung ) 대한신장학회 2021 Kidney Research and Clinical Practice Vol.40 No.2
Background: This study aimed to investigate whether high body mass index (BMI) and presensitization to human leukocyte antigen (HLA) in kidney transplant recipients (KTRs) affected allograft outcomes. Methods: From January 2010 to December 2018, 1,290 kidney transplantations (KTs) were performed at the Seoul St Mary’s Hospital. Of these, 682 cases of ABO-compatible living donor KT patients were enrolled. They were divided into four groups (low BMI-non-sensitized, high BMI-non-sensitized, low BMI-sensitized, and high BMI-sensitized) according to the median BMI value (22.7 kg/m<sup>2</sup>) and HLA presensitization status (anti-HLA antibody mean fluorescence intensity > 3,000). Short-term and long-term allograft outcomes were compared between groups. Results: In the high BMI-sensitized group, the decline in allograft function was higher than that in the other three groups. Death-censored graft loss (DCGL) rates were highest in the high BMI-sensitized group (4 of 21 [19.0%], p = 0.04). In the multivariable Cox regression hazard regression model analysis, the hazard ratio (HR) for DCGL was intensified when high BMI and presensitization statuses were combined (HR, 3.75; p = 0.03); these statuses significantly interacted with each other (p-value for interaction = 0.008). Conclusion: Our results suggest that presensitization to HLA and high BMI might have an interactive adverse impact on allograft outcomes in KTRs.